Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30571219 | 0.91 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL924033 | 0.91 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL4914114 | 0.90 | CNR2 (0.66) | CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL3002214 | 0.90 | CNR2 (0.74) | CNR2CNR1 | |
| SCHEMBL12907702 | 0.89 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL3185493 | 0.88 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL3252718 | 0.88 | CNR1 (0.57) | CNR2CNR1 | |
| SCHEMBL3085088 | 0.87 | CNR1 (0.73) | CNR2CNR1 | |
| SCHEMBL661692 | 0.87 | CNR2 (0.68) | CNR2CNR1 | |
| SCHEMBL2875643 | 0.87 | CNR1 (0.63) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354442-B2 | Imidazol-4-one and imidazole-4-thione compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2013-01-15 | — | — | US | disclosed |
| US-20100234439-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234438-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010062686-A2 | IMIDAZOL-4-ONE AND IMIDAZOLE-4-THIONE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-05-06 | — | — | US | disclosed |
| US-20080146614-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234439-A1 | THERAPEUTIC AGENTS | NLN, GPR119, GRIK5 | CNR2 148/4885CNR1 185/4885 |
| US-20100113546-A1 | Imidazol-4-one and Imidazole-4-thione Compounds | CNR1, CNR2, HRH4 | CNR2 2/4885CNR1 1/4885 |
| US-20080146614-A1 | Therapeutic Agents | BDNF, NLN, GRIN2C | CNR2 480/4885CNR1 597/4885 |
| US-20100234438-A1 | THERAPEUTIC AGENTS | NLN, GPR119, GRIK5 | CNR2 148/4885CNR1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.